Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Elongation factor Tu, mitochondrial (TUFM)
- Target
- TUFM
- Molecular classification
- Enzyme (specifically, GTPase/protein translation elongation factor), Mitochondrial protein, Protein synthesis factor
01
Overview
Elongation factor Tu, mitochondrial (TUFM) is a nuclear-encoded mitochondrial GTPase that mediates a key step in mitochondrial protein synthesis by delivering aminoacyl-tRNAs to the A-site of the mitochondrial ribosome. It is among the most abundant mitochondrial proteins and is structurally and functionally highly conserved from bacteria (EF-Tu) to humans. Besides its canonical role in translation elongation, TUFM regulates mitochondrial autophagy (mitophagy), modulates programmed cell death pathways, and participates in immune responses to viral infection. TUFM mutations cause severe inherited mitochondrial disorders with multi-system involvement, while overexpression or dysregulation has been linked to cancer progression and other diseases. Targeting TUFM function is an emerging therapeutic strategy in oncology and mitochondrial medicine, though significant challenges in safety and specificity remain.
- Other names
- EF-TuEFTuEF-TuMTEFTUP43COXPD4elongation factor Tu, mitochondrialepididymis secretory sperm binding protein
02
Mechanism of action
Inhibition of TUFM-dependent mitochondrial translation (e.g., nanobody-induced cytotoxicity in glioblastoma stem cells); Modulation of mitophagy and apoptosis pathways
03
Biological functions
Mitochondrial protein translationDelivery of aminoacyl-tRNAs to mitochondrial ribosomeRegulation of mitophagy (mitochondrial autophagy)Modulation of programmed cell death (apoptosis, autophagy, necroptosis, pyroptosis)Protein folding and quality control (chaperone activity)Modulation of immune pathways during infection
04
Disease associations
Mitochondrial disorders (OXPHOS defects, combined oxidative phosphorylation deficiency)Cancer (notably glioblastoma and others)Neurodegenerative disease (e.g., multiple sclerosis)Cardiovascular disease (e.g., pulmonary arterial hypertension, diabetic cardiomyopathy)Viral infection (host-pathogen interactions, innate immune modulation)Premature ovarian insufficiency, leukodystrophy
05
Safety considerations
Loss of TUFM function leads to severe mitochondrial dysfunction, lactic acidosis, encephalopathy, and early fatal outcomes in genetic disordersBroad tissue expression means that systemic inhibition may have toxicity concerns, especially for tissues with high energy demand
06
Interacting drugs
anti-TUFM nanobodies (e.g., Nb206)
07
Biomarkers
TUFM protein is suggested as a biomarker for glioblastoma, particularly for distinguishing cancer stem cells from normal tissueExpression correlates with pulmonary arterial hypertension and other disease processes
Beyond the preview
Go deeper on Elongation factor Tu, mitochondrial (TUFM).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Elongation factor Tu, mitochondrial (TUFM).